Pegylated interferon alfa-2b a possible adjuvant treatment option for melanoma

Wen-Jen Hwu
September 2008
Hem/Onc Today;9/10/2008, Vol. 9 Issue 16, p18
The article reports on a study which found that adjuvant pegylated interferon alfa-2b improved the recurrence-free survival in patients with stage III melanoma. Researchers for the European Organization for Research and Treatment of Cancer (EORTC) Melanoma Group stratified the previously grouped participants for microscopic versus macroscopic nodal involvement, number of positive nodes, ulceration and tumor thickness, sex and study center.


Related Articles

  • EORTC: Interferon alfa-2b improved RFS, decreased QOL in stage III melanoma.  // Hem/Onc Today;6/10/2009, Vol. 10 Issue 11, p53 

    The article discusses research on the effect of adjuvant therapy with pegylated interferon alfa-2b on patients with resected stage II melanoma, that references a study by John Glaspy and colleagues published in a 2009 issue of the "Journal of Clinical Oncology."

  • Advances in Adjuvant Therapy for the Treatment of High-risk Melanoma. Grossmann, Kenneth F.; Christiansen, Shelley // Oncology & Hematology Review;Winter2013, Vol. 9 Issue 2, p132 

    The global incidence of melanoma is increasing, and the prognosis for patients remains poor. High-dose interferon-alpha (HD-IFN-α) and pegylated IFN are the only US Food and Drug Administration (FDA)-approved agents for adjuvant therapy for high-risk melanoma, and an improvement in...

  • Swedes approve malignant melanoma treatment.  // Pharmaceutical Technology Europe;Apr2006, Vol. 18 Issue 4, p19 

    The article reports on the Swedish medical products agency's approval for the use of the multisubtype natural human alpha interferon, Multiferon. The product was approved as an adjuvant treatment for high risk malignant melanoma. It will be used after surgical resection of tumors and treatment...

  • Treatment -- Adjuvant and Neoadjuvant Therapy.  // Current Medical Literature: Breast Cancer;2006, Vol. 18 Issue 3, p83 

    The article provides an overview of citations about adjuvant and neoadjuvant cancer therapy. They include "Tamoxifen and Contralateral Breast Cancer in BRCA1 and BRCA2 Carriers: An Update," by J. Gronwald et al, "Tamoxifen After Adjuvant Chemotherapy for Premenopausal Women With Lymph...

  • Ocena tolerancji radykalnego leczenia promieniami chorych na raka piersi powyżej 75. roku życia. Kleszyk, Łukasz; Urbańczyk, Hubert // Menopausal Review / Przeglad Menopauzalny;2012, Vol. 11 Issue 2, p103 

    Introduce and aim of the study: A common problem during radiotherapy of breast cancer patients, is both early (mainly skin reactions) and late (occuring withing months to years after treatment completion) normal Tytissue toxicity. This study aims to evaluate the tolerance of radical radiotherapy...

  • The Influence of Endocrine Effects of Adjuvant Therapy on Quality of Life Outcomes in Younger Breast Cancer Survivors. M. Tish Knobf // Oncologist;Feb2006, Vol. 11 Issue 2, p96 

    SIGNIFICANCE: There are 2.2 million breast cancer survivors, and approximately 25%–30% of newly diagnosed women each year are <50 years of age. Adjuvant therapy has prolonged survival, but the quality of that survival is influenced by persistent and late effects of therapy. Knowledge of...

  • Moxibustion for cancer care: a systematic review and meta-analysis. Myeong Soo Lee; Tae-Young Choi; Ji-Eun Park; Song-Shil Lee; Ernst, Edzard // BMC Cancer;2010, Vol. 10, p130 

    Background: Moxibustion is a traditional Chinese method that uses the heat generated by burning herbal preparations containing Artemisia vulgaris to stimulate acupuncture points. Considering moxibustion is closely related to acupuncture, it seems pertinent to evaluate the effectiveness of...

  • Prognostic significance of autoimmunity during treatment of melanoma with interferon. Krauze, Michal; Tarhini, Ahmad; Gogas, Helen; Kirkwood, John // Seminars in Immunopathology;Dec2011, Vol. 33 Issue 4, p385 

    Since the pivotal cooperative group trials in the 1980's-90's,, high-dose interferon (HDI) has been the standard of adjuvant therapy. Despite multiple other trials evaluating potential new therapies in melanoma, HDI remains the only FDA-approved therapy for stage IIB and III melanoma. Initial...

  • Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis. Mocellin, Simone; Pasquali, Sandro; Rossi, Carlo R.; Nitti, Donato // JNCI: Journal of the National Cancer Institute;4/7/2010, Vol. 102 Issue 7, p493 

    Background: Based on previous meta-analyses of randomized controlled trials (RCTs), the use of interferon alpha (IFN-α) in the adjuvant setting improves disease-free survival (DFS) in patients with high-risk cutaneous melanoma. However, RCTs have yielded conflicting data on the effect of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics